These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18768870)

  • 1. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
    J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
    Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
    Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P; Pan ZK; Paterson Y
    Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
    Betting DJ; Mu XY; Kafi K; McDonnel D; Rosas F; Gold DP; Timmerman JM
    Vaccine; 2009 Jan; 27(2):250-9. PubMed ID: 19000731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW; Young HA; Pennington RW; Weeks SD
    Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
    Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
    Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M; Ochi A
    J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses.
    Muraro S; Bondanza A; Bellone M; Greenberg PD; Bonini C
    Blood; 2005 May; 105(9):3596-604. PubMed ID: 15650058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
    Kaminski MS; Kitamura K; Maloney DG; Levy R
    J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
    Neelapu SS; Baskar S; Kwak LW
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand.
    Huang HI; Wu PY; Teo CY; Chen MN; Chen YC; Silin D; Tao MH
    Int J Cancer; 2004 Feb; 108(5):696-703. PubMed ID: 14696096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
    Cohen S; Haimovich J; Hollander N
    J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
    Musselli C; Livingston PO; Ragupathi G
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.